41 results about "Prehypertension" patented technology

A method that electrically stimulates a heart muscle to alter the ejection profile of the heart, to control the mechanical function of the heart and reduce the observed blood pressure of the patient. The therapy may be invoked by an implantable blood pressure sensor associated with a pacemaker like device. In some cases, where a measured pretreatment blood pressure exceeds a treatment threshold, a patient's heart may be stimulated with an electrical stimulus timed relative to the patient's cardiac ejection cycle. This is done to cause dyssynchrony between at least two cardiac chambers or within a cardiac chamber, which alters the patient's cardiac ejection profile from a pretreatment cardiac ejection profile. This has the effect of reducing the patient's blood pressure from the measured pretreatment blood pressure.

A method that electrically stimulates a heart muscle to alter the ejection profile of the heart, to control the mechanical function of the heart and reduce the observed blood pressure of the patient. The therapy may be invoked by an implantable blood pressure sensor associated with a pacemaker like device. In some cases, where a measured pretreatment blood pressure exceeds a treatment threshold, a patient's heart may be stimulated with an electrical stimulus timed relative to the patient's cardiac ejection cycle. This is done to cause dyssynchrony between at least two cardiac chambers, which alters the patient's cardiac ejection profile from a pretreatment cardiac ejection profile. This has the effect of reducing the patient's blood pressure from the measured pretreatment blood pressure.

The invention discloses a novel use of a novel use of growth-differential factor 15 (GDF15) in assessment of first cerebral stroke of a hypertension patient. The GDF15 is used as a marker for assessment of a first cerebral stroke risk of a subject to be detected. The invention also provides a use of a reagent for detecting a GDF15 level in a detection agent or detection system for assessment of a first cerebral stroke risk of a subject to be detected and also provides a detection system for assessment of a first cerebral stroke risk of a subject to be detected. A hypertension cohort population perspective research proves that the hypertensive patient with a high baseline blood plasma GDF15 level has a high risk of first cerebral stroke and cerebral ischemic stroke.

A bypass device for influencing blood pressure, including an implant with a volumetric chamber, having a connector or connecting means for connecting the volumetric chamber to a natural cardiovascular system, and having an adaptor or adaptation means, by which a change in volume of a volume of the volumetric chamber is enabled or effected upon a pressure change in the cardiovascular system or in the volumetric chamber. According to this invention, a change in volume in a lower pressure range between 50 mmHg and a pressure threshold value amounting to at least 100 mmHg amounts to at most 10 cm3, and in an upper pressure range between the pressure threshold value and 150 mmHg amounts to at least 10 cm3. With the device according to this invention, high blood pressure can be reduced in a carefully directed way.

The present invention relates to the new use of alpha-ketoglutarate, amides, and salts and mixtures thereof for the manufacture of a pharmaceutical preparation or a food or feed supplement for the in vivo therapeutic improvement of blood vessel elasticity, in particular arterial elasticity in a subject in need thereof. Improving the blood vessel elasticity may be used in the for the treatment and / or prophylaxis of hypertension, pulmonary arterial hypertension, cardiovascular disease, retinal vascular disease, heart failure, atherosclerosis, ventricular hypertrophy, stroke, arterial aneurysm, kidney failure, nephrosclerosis and diseases related to hypertension.

The invention discloses a human body blood pressure limiter which comprises a valve body and a valve core which are arranged in a human body; the area of the front end of the valve core is A; a spring with the elastic force of F is arranged between the upper end of the valve core and that of a valve cavity; a blood inlet is formed on one side of the valve cavity, the inner port of the blood inlet is communicated with the valve cavity, and the outer port is communicated with arterial vessels of the human body through artificial blood vessels; a valve-in pipeline is arranged at the blood inlet and is communicated with the bottom of the valve cavity; a blood outlet is formed on the other side of the valve cavity and is led out of the human body or is communicated with the vein vessels of the human body through the artificial blood vessels; the dangerous critical blood pressure of the human body is set as P; A and F meet the condition that F equals to P multiplied by A; when the blood pressure of the human body is higher than P, the valve core moves upwards, a part of blood flows out of the human body or flows into the vein vessels of the human body from the arterial vessels of the human body through the blood inlet and outlet; and when the blood pressure of the human body is lower than P, the valve core moves downwards so as to block the blood inlet and the blood outlet. The human body blood pressure limiter can limit rising of the blood pressure automatically under the emergent situation that the blood pressure of hypertension personnel rises sharply and seriously threatens lives.

The present invention relates to methods of treating subjects suffering from pre-hypertension or hypertension by administering to a subject in need of treatment thereof a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof.

The present application provides methods for treating cardiovascular conditions. The methods can include administering a Transient Receptor Potential Vanilloid 1 (TRPV1) receptor agonist to an epidural space. The methods can be used to treat a variety of conditions such as hypertension, prehypertension, mild hypertension, severe hypertension, refractory hypertension, congestive heart failure and myocardial scarring.